Solving The Patient Diversity Problem

Patient diversity remains a hot topic in clinical trials. Regulators are focused on increasing diversity in patient populations while sponsor companies, CROs, and sites continue to struggle to find the right balance of gender and ethnic participation. What everyone would like to know is where we are now and where we go from here.

In October 2020, Clinical Leader Chief Editor, Ed Miseta, had the opportunity to sit down with Cassandra Smith of Janssen, Robin Weinick of DIA, and RADM Richardae Araojo of FDA to discuss the advances we have made in patient diversity, what the FDA and sponsor companies are doing, and why there is so much more we need to do.